News Releases

-- Data Presented at 2017 San Antonio Breast Cancer Symposium -- SEATTLE --(BUSINESS WIRE)--Dec. 6, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced results of a

New preclinical data to be presented at multiple upcoming scientific meetings Strong balance sheet with $87.2 million in cash, cash equivalents, and short-term investments SEATTLE --(BUSINESS WIRE)--Nov. 13, 2017-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading immunotherapy company focused

-- Company’s vIgD Platform Well Positioned to Realize Next Generation Immuno-Oncology Therapeutics -- SEATTLE --(BUSINESS WIRE)--Nov. 10, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and

--Poster to be Presented at 2017 ACR/ARHP Annual Meeting-- SEATTLE --(BUSINESS WIRE)--Nov. 6, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced results from preclinical studies

SEATTLE --(BUSINESS WIRE)--Nov. 1, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced the company will present at two upcoming investor conferences in November.

SEATTLE --(BUSINESS WIRE)--Oct. 23, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced it has extended the research term of its worldwide research and license agreement with Kite, a

SEATTLE --(BUSINESS WIRE)--Oct. 16, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced planned poster presentations highlighting recent data at the following scientific

SEATTLE --(BUSINESS WIRE)--Sep. 20, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced a planned poster presentation highlighting recent data from a preclinical study

SEATTLE --(BUSINESS WIRE)--Sep. 13, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on the development of treatments for autoimmune/inflammatory diseases and cancer, announced today that the company will present at the Ladenburg Thalmann 2017 Healthcare

- Commences Trading on NASDAQ Global Market on July 25, 2017 under Ticker Symbol “ALPN” - - Utilizes Novel Protein-Based Immunotherapy Discovery Platform Focused on Developing Therapeutics for the Potential Treatment of Inflammatory Diseases and Cancer - - Approximately $90 Million in Cash and Cash